TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3b Multicenter, Single-Blind Trial to Evaluate the Efficacy of Dexlansoprazole MR 30 mg in Maintaining Control of Gastroesophageal Reflux Disease Symptoms in Subjects on Prior Twice Daily Proton Pump Inhibitor Therapy
Brief Summary: The purpose of this study is to determine if patients with well-controlled heartburn symptoms on twice-daily proton pump inhibitor therapy remain well-controlled after stepping down to once-daily (QD) dexlansoprazole modified release (MR) 30 mg.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Dexlansoprazole MR QD | Intervention Type: DRUG; Name: Dexlansoprazole MR QD; Assigned to Arm(s): 1
B: Arm Label: Esomeprazole 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Esomeprazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Esomeprazole | Intervention Type: DRUG; Name: Esomeprazole; Assigned to Arm(s): Esomeprazole 20 mg, Placebo
C: Arm Label: Dexlansoprazole MR 60 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Dexlansoprazole MR | Arm Label: Dexlansoprazole MR 90 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Dexlansoprazole MR | Intervention Type: DRUG; Name: Dexlansoprazole MR; Assigned to Arm(s): Dexlansoprazole MR 60 mg QD | Intervention Type: DRUG; Name: Dexlansoprazole MR; Assigned to Arm(s): Dexlansoprazole MR 90 mg QD
D: Arm Label: Esomeprazole 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Esomeprazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Esomeprazole | Intervention Type: DRUG; Name: Esomeprazole; Assigned to Arm(s): Esomeprazole 20 mg, Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intérêt d'Utiliser Des solutés de Remplissage équilibrés à la Phase précoce d'un Traumatisme crânien Grave Pour Limiter l'Acidose hyperchlorémique
Brief Summary: isotonic NaCl serum is the first intent solution for infusion during the initial phase of reanimation for an acute cranial traumatism.

However, its use can trigger an hyperchloremic metabolic acidosis, what could be deleterious for the future of this patient.

Isofundine present all charateristics to be use in this indication: pharmacokinetic and pharmacodynamic similar to the physiologic serum, iso-osmolarity to plasma, no glucose provision and no interaction with hemostasis.


Options:
A: Arm Label: Lactated ringers solution; Type: EXPERIMENTAL; Interventions: Drug: Lactated Ringer Solution | Arm Label: Normal saline solution; Type: EXPERIMENTAL; Interventions: Drug: Normal Saline 0.9% Infusion Solution Bag | Intervention Type: DRUG; Name: Lactated Ringer Solution; Assigned to Arm(s): Lactated ringers solution | Intervention Type: DRUG; Name: Normal Saline 0.9% Infusion Solution Bag; Assigned to Arm(s): Normal saline solution
B: Arm Label: Adult ICU patient receiving Fluid resus; Type: N/A; Interventions: N/A
C: Arm Label: Intravenous fluids; Type: OTHER; Interventions: Drug: Lower chloride fluids (Hartmann's solution and Plasmalyte®) | Intervention Type: DRUG; Name: Lower chloride fluids (Hartmann's solution and Plasmalyte®); Assigned to Arm(s): Intravenous fluids
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: use of a non balced fluid and of a macromolecular fluid | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: use of balanced crystalloids fluid and macromolecular fluid | Intervention Type: DRUG; Name: use of a non balced fluid and of a macromolecular fluid; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: use of balanced crystalloids fluid and macromolecular fluid; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective Study to Establish Normative Values, Demographic Variations, Referent Diagnostic Values and Disease Severity Correlations for Dry Eye Disease and TearLab Osmometry.
Brief Summary: This is a prospective, observational case series to determine the clinical utility of tear osmolarity and other commonly used objective tests to diagnose dry eye disease, as well as to establish referent values for objective tests of the disease.


Options:
A: Arm Label: Normal; Type: N/A; Interventions: N/A | Arm Label: Dry Eye Disease; Type: N/A; Interventions: N/A
B: Arm Label: Severe dry eye; Type: EXPERIMENTAL; Interventions: Drug: 0.02% Fm, SH, Drug: 0.02% Fm, SH, 0.05% CsA, Other: 0.02% Fm, SH, tBCL, Drug: 0.02% Fm, SH, AS | Intervention Type: DRUG; Name: 0.02% Fm, SH; Assigned to Arm(s): Severe dry eye | Intervention Type: DRUG; Name: 0.02% Fm, SH, 0.05% CsA; Assigned to Arm(s): Severe dry eye | Intervention Type: OTHER; Name: 0.02% Fm, SH, tBCL; Assigned to Arm(s): Severe dry eye | Intervention Type: DRUG; Name: 0.02% Fm, SH, AS; Assigned to Arm(s): Severe dry eye
C: Arm Label: Autologous serum -Systane; Type: OTHER; Interventions: Drug: Autologous serum - Systane | Arm Label: Systane- Autologous serum; Type: OTHER; Interventions: Drug: Systane - Autologous serum | Intervention Type: DRUG; Name: Autologous serum - Systane; Assigned to Arm(s): Autologous serum -Systane | Intervention Type: DRUG; Name: Systane - Autologous serum; Assigned to Arm(s): Systane- Autologous serum
D: Arm Label: UCB eyedrops, single arm; Type: N/A; Interventions: Other: UCS eyedrops | Intervention Type: OTHER; Name: UCS eyedrops; Assigned to Arm(s): UCB eyedrops, single arm

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective Study to Establish Normative Values, Demographic Variations, Referent Diagnostic Values and Disease Severity Correlations for Dry Eye Disease and TearLab Osmometry.
Brief Summary: This is a prospective, observational case series to determine the clinical utility of tear osmolarity and other commonly used objective tests to diagnose dry eye disease, as well as to establish referent values for objective tests of the disease.


Options:
A: Arm Label: Normal; Type: N/A; Interventions: N/A | Arm Label: Dry Eye Disease; Type: N/A; Interventions: N/A
B: Arm Label: SB; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Sea buckthorn (Hippophaë rhamnoides) oil | Arm Label: PL; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo comparison | Intervention Type: DIETARY_SUPPLEMENT; Name: Sea buckthorn (Hippophaë rhamnoides) oil; Assigned to Arm(s): SB | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo comparison; Assigned to Arm(s): PL
C: Arm Label: Omega-3 supplements; Type: EXPERIMENTAL; Interventions: Drug: Omega-3 supplements | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Omega-3 supplements; Assigned to Arm(s): Omega-3 supplements | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Other: Inactive Capsule | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Hydroeye | Intervention Type: DIETARY_SUPPLEMENT; Name: Hydroeye; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Inactive Capsule; Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective Study to Establish Normative Values, Demographic Variations, Referent Diagnostic Values and Disease Severity Correlations for Dry Eye Disease and TearLab Osmometry.
Brief Summary: This is a prospective, observational case series to determine the clinical utility of tear osmolarity and other commonly used objective tests to diagnose dry eye disease, as well as to establish referent values for objective tests of the disease.


Options:
A: Arm Label: Normal; Type: N/A; Interventions: N/A | Arm Label: Dry Eye Disease; Type: N/A; Interventions: N/A
B: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Procedure: Thermal Pulsation therapy | Intervention Type: PROCEDURE; Name: Thermal Pulsation therapy; Assigned to Arm(s): Treatment
C: Arm Label: EyeGiene; Type: ACTIVE_COMPARATOR; Interventions: Device: EyeGiene | Arm Label: Blephasteam; Type: ACTIVE_COMPARATOR; Interventions: Device: Blephasteam | Arm Label: Control- Hot Compress; Type: PLACEBO_COMPARATOR; Interventions: Device: Hot compresses | Intervention Type: DEVICE; Name: Blephasteam; Assigned to Arm(s): Blephasteam | Intervention Type: DEVICE; Name: EyeGiene; Assigned to Arm(s): EyeGiene | Intervention Type: DEVICE; Name: Hot compresses; Assigned to Arm(s): Control- Hot Compress
D: Arm Label: Standard Lid Hygiene Regime; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lid hygiene regime | Arm Label: Lipiflow; Type: ACTIVE_COMPARATOR; Interventions: Device: Lipiflow | Intervention Type: DEVICE; Name: Lipiflow; Assigned to Arm(s): Lipiflow | Intervention Type: BEHAVIORAL; Name: Lid hygiene regime; Assigned to Arm(s): Standard Lid Hygiene Regime

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Diabetes Management in Low-Income Hispanic Patients
Brief Summary: The overall goal of this randomized clinical trial (RCT) is to test the efficacy of a culturally- and literacy-tailored cognitive-behavioral intervention designed to enhance adherence to diabetes self-management behaviors and improve glycemic control among low-income Hispanic individuals with type 2 diabetes mellitus.


Options:
A: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Enhanced; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Written educational brochure | Arm Label: Interpersonal; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Written educational brochure, Behavioral: Promotora interaction | Intervention Type: BEHAVIORAL; Name: Written educational brochure; Assigned to Arm(s): Enhanced, Interpersonal | Intervention Type: BEHAVIORAL; Name: Promotora interaction; Assigned to Arm(s): Interpersonal
B: Arm Label: A; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Support for Increased Physical Activity | Intervention Type: BEHAVIORAL; Name: Support for Increased Physical Activity; Assigned to Arm(s): B
C: Intervention Type: BEHAVIORAL; Name: Self-Help Intervention Program-High Blood Pressure; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Intervention | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Intervention; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open-label Study In The Latin America Region Comparing The Safety And Efficacy Of Etanercept With Conventional Dmard Therapy In Subjects With Rheumatoid Arthritis.
Brief Summary: The purpose of this 2 phased, open-label study is to compare the safety and efficacy of etanercept with conventional Disease Modifying Antirheumatic Drug (DMARD) therapy in Latin American subjects with moderate to severe rheumatoid arthritis over 128 weeks. Phase 1 is a randomized 24 week treatment period; Phase 2 is an optional open-label 104 week period that allows the investigator to choose continuation with the phase I treatment or the addition, discontinuation or titration of other DMARD therapy already being utilized for the study.


Options:
A: Arm Label: Phase 1 Etanercept + methotrexate; Type: EXPERIMENTAL; Interventions: Biological: Phase 1: Etanercept, Drug: Phase 1: Methotrexate, Drug: Phase 2: Optional ETN, SSZ, HCQ, MTX | Arm Label: Phase 1 Conventional DMARD (SSZ or HCQ) + MTX; Type: ACTIVE_COMPARATOR; Interventions: Drug: Phase 1: Methotrexate, Drug: Phase 1: Conventiaonal DMARD | Intervention Type: BIOLOGICAL; Name: Phase 1: Etanercept; Assigned to Arm(s): Phase 1 Etanercept + methotrexate | Intervention Type: DRUG; Name: Phase 1: Methotrexate; Assigned to Arm(s): Phase 1 Etanercept + methotrexate | Intervention Type: DRUG; Name: Phase 2: Optional ETN, SSZ, HCQ, MTX; Assigned to Arm(s): Phase 1 Etanercept + methotrexate | Intervention Type: DRUG; Name: Phase 1: Methotrexate; Assigned to Arm(s): Phase 1 Conventional DMARD (SSZ or HCQ) + MTX | Intervention Type: DRUG; Name: Phase 1: Conventiaonal DMARD; Assigned to Arm(s): Phase 1 Conventional DMARD (SSZ or HCQ) + MTX
B: Arm Label: Open Label Infliximab + Methotrexate; Type: EXPERIMENTAL; Interventions: Biological: Infliximab + methotrexate (MTX) | Intervention Type: BIOLOGICAL; Name: Infliximab + methotrexate (MTX); Assigned to Arm(s): Open Label Infliximab + Methotrexate
C: Arm Label: Tocilizumab 162 mg sc; Type: EXPERIMENTAL; Interventions: Drug: Tocilizumab 162 mg | Arm Label: Placebo sc; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tocilizumab 162 mg; Assigned to Arm(s): Tocilizumab 162 mg sc | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo sc
D: Arm Label: 5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 15 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 30 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 5 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 15 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 30 mg BID | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Risperidone Maintenance Treatment for Relapse Prevention in Schizophrenia
Brief Summary: This study set out to determine the duration of maintenance treatment with therapeutic risperidone dose in schizophrenia. In a multi-center, open label, randomized, controlled study design, patients with schizophrenia who were clinically stabilized following an acute episode were randomly assigned to a 'maintenance group' (optimal therapeutic doses continued for at least 1 year), a 4-week group (optimal therapeutic doses continued for 4 weeks followed by a 50% dose reduction that was maintained for at least 11 months) or a 26-week group (optimal therapeutic doses continued for 26 weeks followed by a 50% dose reduction for at least another 6 months).


Options:
A: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Paliperidone Palmitate | Arm Label: 002; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Paliperidone Palmitate; Assigned to Arm(s): 001
B: Intervention Type: DRUG; Name: Risperidone, long-acting injectable; Assigned to Arm(s): N/A
C: Arm Label: Bifeprunox; Type: EXPERIMENTAL; Interventions: Drug: Bifeprunox | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Quetiapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Quetiapine | Intervention Type: DRUG; Name: Bifeprunox; Assigned to Arm(s): Bifeprunox | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): Quetiapine
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: risperidone | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: risperidone | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: risperidone | Intervention Type: DRUG; Name: risperidone; Assigned to Arm(s): 1, 2, 3

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Controlled Clinical Trial of the Effect of Increases Time Outdoors in the Prevention of Juvenile-onset Myopia in Chinese Children
Brief Summary: The purpose of this study is to assess whether outdoor activities are effective in preventing the development and progression of juvenile-onset myopia in Chinese children.


Options:
A: Arm Label: Bifocal spectacles; Type: ACTIVE_COMPARATOR; Interventions: Device: Bifocal spectacles | Arm Label: Prismatic bifocals; Type: ACTIVE_COMPARATOR; Interventions: Device: Prismatic bifocal spectacles | Arm Label: Single vision spectacles; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Bifocal spectacles; Assigned to Arm(s): Bifocal spectacles | Intervention Type: DEVICE; Name: Prismatic bifocal spectacles; Assigned to Arm(s): Prismatic bifocals
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Outdoor activity; Type: EXPERIMENTAL; Interventions: Behavioral: Outdoor activity | Intervention Type: BEHAVIORAL; Name: Outdoor activity; Assigned to Arm(s): Outdoor activity
C: Arm Label: omafilcon A; Type: EXPERIMENTAL; Interventions: Device: omafilcon A | Arm Label: Spectacle Group; Type: ACTIVE_COMPARATOR; Interventions: Device: Spectacle | Intervention Type: DEVICE; Name: omafilcon A; Assigned to Arm(s): omafilcon A | Intervention Type: DEVICE; Name: Spectacle; Assigned to Arm(s): Spectacle Group
D: Arm Label: Orthokeratology lenses; Type: EXPERIMENTAL; Interventions: Device: Orthokeratology lenses | Arm Label: Single-vision spectacle lenses; Type: OTHER; Interventions: Device: Single-vision spectacle lenses | Intervention Type: DEVICE; Name: Orthokeratology lenses; Assigned to Arm(s): Orthokeratology lenses | Intervention Type: DEVICE; Name: Single-vision spectacle lenses; Assigned to Arm(s): Single-vision spectacle lenses

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Controlled Clinical Trial of the Effect of Increases Time Outdoors in the Prevention of Juvenile-onset Myopia in Chinese Children
Brief Summary: The purpose of this study is to assess whether outdoor activities are effective in preventing the development and progression of juvenile-onset myopia in Chinese children.


Options:
A: Arm Label: Progressive Addition Lenses (PALs); Type: EXPERIMENTAL; Interventions: Other: Progressive Addition Lenses | Arm Label: Single Vision Lenses; Type: ACTIVE_COMPARATOR; Interventions: Other: single vision lenses | Intervention Type: OTHER; Name: Progressive Addition Lenses; Assigned to Arm(s): Progressive Addition Lenses (PALs) | Intervention Type: OTHER; Name: single vision lenses; Assigned to Arm(s): Single Vision Lenses
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Outdoor activity; Type: EXPERIMENTAL; Interventions: Behavioral: Outdoor activity | Intervention Type: BEHAVIORAL; Name: Outdoor activity; Assigned to Arm(s): Outdoor activity
C: Intervention Type: DRUG; Name: 0.25 % atropine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: 0.5 % atropine; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: 0.25 % atropine+auricular acupoints; Assigned to Arm(s): N/A
D: Arm Label: Single-vision glasses; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Orthokeratology with normal compression factor; Type: SHAM_COMPARATOR; Interventions: Device: Orthokeratology | Arm Label: Orthokeratology with increased compression factor; Type: ACTIVE_COMPARATOR; Interventions: Device: Orthokeratology | Intervention Type: DEVICE; Name: Orthokeratology; Assigned to Arm(s): Orthokeratology with increased compression factor, Orthokeratology with normal compression factor

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Rehabilitation With Versus Without Progressive Strength Training Implemented in the Acute Ward After Hip Fracture Surgery: A Randomized Controlled Trial
Brief Summary: The purpose of this study is to examine the effect of progressive strength training of the fractured limb in patients with hip fracture, during admittance in an acute orthopedic ward. The primary study hypothesis is that the training will reduce the strength deficit in the fractured limb in comparison with the non-fractured limb. Secondary, that patients following the intervention will present larger improvements in physical function compared to controls.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Strong for Life | Arm Label: cardiovascular education (attention control); Type: PLACEBO_COMPARATOR; Interventions: Behavioral: cardiovascular nutrition education | Intervention Type: BEHAVIORAL; Name: Enhanced Strong for Life; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: cardiovascular nutrition education; Assigned to Arm(s): cardiovascular education (attention control)
B: Arm Label: Rehabilitation without strength training; Type: ACTIVE_COMPARATOR; Interventions: Other: Rehabilitation without strength training | Arm Label: Rehabilitation with strength training; Type: EXPERIMENTAL; Interventions: Other: Rehabilitation with strength training | Intervention Type: OTHER; Name: Rehabilitation with strength training; Assigned to Arm(s): Rehabilitation with strength training | Intervention Type: OTHER; Name: Rehabilitation without strength training; Assigned to Arm(s): Rehabilitation without strength training
C: Arm Label: PUSH and Nutrition; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Nutrition, Behavioral: PUSH | Arm Label: PULSE and Nutrition; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Nutrition, Behavioral: PULSE | Intervention Type: DIETARY_SUPPLEMENT; Name: Nutrition; Assigned to Arm(s): PULSE and Nutrition, PUSH and Nutrition | Intervention Type: BEHAVIORAL; Name: PUSH; Assigned to Arm(s): PUSH and Nutrition | Intervention Type: BEHAVIORAL; Name: PULSE; Assigned to Arm(s): PULSE and Nutrition
D: Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Arm Label: Intensive physiotherapy; Type: EXPERIMENTAL; Interventions: Other: Intensive physiotherapy | Intervention Type: OTHER; Name: Intensive physiotherapy; Assigned to Arm(s): Intensive physiotherapy | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual care

Answer: B